Company news
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) news
Galmed Pharmaceuticals Ltd. news releases on 6ix. Latest, Dec 14, 2022: Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet…
Press releases — page 2
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
December 13, 2022
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 3, 2022
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
July 6, 2022
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
May 16, 2022
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
May 1, 2022
Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
April 27, 2022
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
April 25, 2022
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
January 10, 2022
Galmed announces positive results of Phase 1 study of Amilo-5MER
January 9, 2022
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
November 7, 2021
Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement
November 7, 2021
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
October 31, 2021
Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
August 18, 2021
MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
August 15, 2021
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
August 4, 2021
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
August 1, 2021
Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5
July 28, 2021
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
May 12, 2021
Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study
May 2, 2021
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
March 17, 2021
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
March 15, 2021
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
March 10, 2021
Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares
February 15, 2021
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
February 15, 2021
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action
January 25, 2021
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
December 16, 2020
Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 11, 2020
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol
November 8, 2020
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
August 5, 2020
Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program
August 5, 2020
Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
May 13, 2020
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
May 6, 2020
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2019 Financial Results
March 11, 2020
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
March 4, 2020
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
November 5, 2019
Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6
October 29, 2019
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
August 4, 2019
Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
July 28, 2019
Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3
April 8, 2019